Publication: Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results From the TIME study
1
Issued Date
2012-08-01
Resource Type
ISSN
10779450
15254135
15254135
Other identifier(s)
2-s2.0-84864284154
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Acquired Immune Deficiency Syndromes. Vol.60, No.4 (2012), 377-383
Suggested Citation
Weerawat Manosuthi, Wiroj Mankatitham, Aroon Lueangniyomkul, Supeda Thongyen, Sirirat Likanonsakul, Pawita Suwanvattana, Unchana Thawornwan, Busakorn Suntisuklappon, Samruay Nilkamhang, Somnuek Sungkanuparph Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results From the TIME study. Journal of Acquired Immune Deficiency Syndromes. Vol.60, No.4 (2012), 377-383. doi:10.1097/QAI.0b013e31825b5e06 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/14705
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results From the TIME study
Other Contributor(s)
Abstract
Background: Optimal timing for initiation of antiretroviral therapy (ART) among HIV-infected patients with tuberculosis (TB) is not well established. Methods: HIV/TB-coinfected patients were randomized to initiate tenofovir/lamivudine/efavirenz at 4 weeks (4-week group) or 12 weeks (12-week group) of TB treatment. The primary outcome was 1-year all-cause mortality. Results: Of 156 patients, 79 were in 4-week group and 77 in 12-week group. Overall, median (interquartile range) CD4 was 43 (47-106) cells per cubic millimeter and median (interquartile range) HIV-1 RNA was 5.8 (5.4-6.3) log copies per milliliter. Eleven (7%) mortalities occurred in a total follow-up period of 137 patient-years. Seven percent (6/79, 8.76 per 100 patient-years) mortalities were in 4-week group, and 6% (5/77, 7.25 per 100 person-years) mortalities were in 12-week group [relative risk (RR) = 0.845, 95% confidence interval (CI) = 0.247 to 2.893]. Twenty-eight (35%) patients in 4-week group and 25 (32%) patients in 12-week group were hospitalized (RR = 1.142, 95% CI = 0.588 to 2.217). Grade 2-4 adverse events were 39% (31/79) in 4-week group and 34% (26/77) in 12-week group (RR = 1.267, 95% CI = 0.659 to 2.435). In multivariate analysis, "low albumin" (RR = 2.695, 95% CI = 1.353 to 5.475) and "low baseline CD4 count" (RR = 4.878, 95% CI = 1.019 to 23.256) were the independent predictors of mortality. Immune reconstitution inflammatory syndrome was more frequent in 4-week group with an incidence of 8.86 versus 5.02 per 100 person-months in 12-week group over the first 6 months of ART (P = 0.069). Conclusions: In middle-income countries where ART is initiated at CD4 count of < 350 cells per cubic millimeter, immediate initiation of ART in HIV-infected patients with active TB was not associated with survival advantage when compared to initiation of ART at 12 weeks. © 2012 by Lippincott Williams & Wilkins.